SCHEMBL6453593

SCHEMBL6453593

O=C(O)CC(O)CC(O)CC(=O)O

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A6 Q4U2R8 1/20 0.75
GABRR1 P24046 2/20 0.60
LMNA P02545 1/20 0.60
MAPT P10636 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.50
GPR84 Q9NQS5 4/20 0.46
TDP1 Q9NUW8 1/20 0.45
TSHR P16473 1/20 0.39
MMP2 P08253 1/20 0.38
MMP9 P14780 1/20 0.38
MMP12 P39900 1/20 0.38
MMP13 P45452 1/20 0.38
MMP14 P50281 1/20 0.38
CACNA2D1 P54289 2/20 0.37
CACNB3 P54284 1/20 0.37
CACNA1C Q13936 1/20 0.37
PGR P06401 1/20 0.37
ADRA1A P35348 1/20 0.37
HTR2B P41595 1/20 0.37
CACNA2D2 Q9NY47 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6557026 0.89 SLC22A6 (0.60) SLC22A6GABRR1LMNAMAPTSMN1; SMN2
SCHEMBL1135908 0.89 SLC22A6 (0.60) SLC22A6GABRR1LMNAMAPTSMN1; SMN2
SCHEMBL4671010 0.89 SLC22A6 (0.60) SLC22A6GABRR1LMNAMAPTSMN1; SMN2
SCHEMBL25427974 0.88 SLC22A6 (0.67) SLC22A6GABRR1LMNAMAPTSMN1; SMN2
SCHEMBL15627218 0.87 SLC22A6 (0.57) SLC22A6GABRR1LMNAMAPTSMN1; SMN2
SCHEMBL1135965 0.87 SLC22A6 (0.57) SLC22A6GABRR1LMNAMAPTSMN1; SMN2
SCHEMBL8893405 0.87 SLC22A6 (0.57) SLC22A6GABRR1LMNAMAPTSMN1; SMN2
SCHEMBL15627219 0.87 SLC22A6 (0.57) SLC22A6GABRR1LMNAMAPTSMN1; SMN2
SCHEMBL17204173 0.87 SLC22A6 (0.57) SLC22A6GABRR1LMNAMAPTSMN1; SMN2
SCHEMBL8893398 0.87 SLC22A6 (0.57) SLC22A6GABRR1LMNAMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295195-A1 ANTIMICROBIAL ORGANOSILANES Tipikos Pharmaceuticals, Inc. (US) 2023-09-21 US disclosed
US-20230143708-A1 ANTIMICROBIAL ORGANOSILANES TOPIKOS PHARMACEUTICALS, INC. (US) 2023-05-11 US disclosed
EP-1049784-B1 POLYHYDROXYALKANOATE BIOSYNTHESIS-RELATED GENES DERIVED FROM ALCALIGENES LATUS LG CHEMICAL LTD (KR) 2005-04-20 EP disclosed
US-6649382-B1 Culturing cell transformed with a expression vector comprising DNA fragment with three open reading frames; synthase, beta-ketothiolase and acetoacetyl-CoA reductase; biodegradable LG CHEMICAL LTD. (KR) 2003-11-18 US disclosed
EP-1049784-A1 POLYHYDROXYALKANOATE BIOSYNTHESIS-RELATED GENES DERIVED FROM ALCALIGENES LATUS LG CHEMICAL LTD. (KR) 2000-11-08 EP disclosed
WO-1999036547-A1 POLYHYDROCYALKANOATE BIOSYNTHESIS-RELATED GENES DERIVED FROM $i(ALCALIGENES LATUS) LG CHEMICAL LTD. (KR) 1999-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230143708-A1 ANTIMICROBIAL ORGANOSILANES ARG1, ACMSD, AAAS SLC22A6 1842/4885GABRR1 3637/4885LMNA 4596/4885
US-20230295195-A1 ANTIMICROBIAL ORGANOSILANES ARG1, ACMSD, AAAS SLC22A6 1842/4885GABRR1 3637/4885LMNA 4596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.